Guardant Health director converts 154 RSUs to shares

Guardant Health director Steve E. Krognes reported the vesting and conversion of restricted stock units into common shares.

Rhea-AI Filing Summary

Guardant Health director Steve E. Krognes reported the vesting and conversion of restricted stock units into common shares. On August 9, 2022 he received a restricted stock unit award that began vesting June 30, 2023, with 25% vesting then and the remaining 75% vesting in equal monthly installments over three years. On February 28, 2026, 154 restricted stock units vested and were converted at no cost into 154 shares of Guardant Health common stock. After these transactions, he directly held 618 restricted stock units and 19,053 shares of common stock.

Insider Trade Summary

154 shares exercised/converted

Exercise 2 txns

Insider Krognes Steve E.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	154	$0.00	$0.00
Exercise	Common Stock	154	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 618 contracts (Direct); Common Stock — 19,053 shares (Direct)

Footnotes (2)

1. F1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.
2. F2. Not applicable for Restricted Stock Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) director Steve E. Krognes report?

Steve E. Krognes reported the vesting and conversion of 154 restricted stock units into 154 shares of Guardant Health common stock. These shares came from a previously granted equity award and were acquired at no cash cost to him as part of his compensation.

How many Guardant Health restricted stock units vested in the latest Form 4?

A total of 154 restricted stock units vested for Steve E. Krognes. These units are part of an award granted on August 9, 2022 that vests monthly after June 30, 2023, and they were converted into an equal number of Guardant Health common shares.

What is the vesting schedule of Steve Krognes’ Guardant Health RSU award?

The RSU award was granted August 9, 2022, with 25% of the shares vesting on June 30, 2023. The remaining 75% vests in substantially equal installments on each monthly anniversary of June 30, 2023 over the following three-year period.

How many Guardant Health shares does Steve Krognes hold after the reported transactions?

After the reported February 28, 2026 transactions, Steve Krognes directly holds 19,053 shares of Guardant Health common stock. He also directly holds 618 restricted stock units, representing additional stock-based compensation that will settle into shares as they vest.

Did Steve Krognes buy or sell Guardant Health stock in this Form 4?

The Form 4 shows an exercise or conversion of derivative securities, not an open-market purchase or sale. Steve Krognes acquired 154 Guardant Health common shares at a price of $0.00 per share through vesting of previously granted restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/28/2026		M		154	A	$0	19,053	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/28/2026		M			154	(1)	(2)	Common Stock	154	$0	618	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on August 9, 2022 that vested as to 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.